Organon & Co. (NYSE:OGN) Sets New 1-Year High – Here’s What Happened

Organon & Co. (NYSE:OGN)’s share price hit a new 52-week high on Wednesday . The company traded as high as $13.39 and last traded at $13.3750, with a volume of 1771894 shares changing hands. The stock had previously closed at $13.35.

Wall Street Analyst Weigh In

OGN has been the subject of a number of research reports. Barclays boosted their target price on shares of Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research note on Tuesday, February 24th. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Piper Sandler upgraded Organon & Co. from an “underweight” rating to a “neutral” rating and upped their price objective for the company from $5.00 to $14.00 in a research report on Tuesday, April 28th. BNP Paribas Exane reaffirmed a “neutral” rating and set a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Finally, Wall Street Zen downgraded shares of Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Four equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $11.40.

Organon & Co. Trading Up 0.2%

The stock has a 50-day moving average price of $8.00 and a two-hundred day moving average price of $7.82. The stock has a market capitalization of $3.50 billion, a PE ratio of 14.35, a PEG ratio of 1.24 and a beta of 1.57. The company has a debt-to-equity ratio of 9.47, a quick ratio of 1.23 and a current ratio of 1.97.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, April 30th. The company reported $0.71 EPS for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the business posted $1.02 EPS. Organon & Co.’s revenue was down 3.5% on a year-over-year basis. As a group, equities analysts forecast that Organon & Co. will post 3.23 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Monday, May 11th will be paid a dividend of $0.02 per share. The ex-dividend date is Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.’s payout ratio is 8.60%.

Insiders Place Their Bets

In other Organon & Co. news, SVP Lynette Holzbaur purchased 26,448 shares of the business’s stock in a transaction on Wednesday, May 6th. The stock was acquired at an average price of $13.35 per share, for a total transaction of $353,080.80. Following the purchase, the senior vice president owned 52,851 shares of the company’s stock, valued at approximately $705,560.85. This represents a 100.17% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.62% of the company’s stock.

Institutional Trading of Organon & Co.

Institutional investors have recently made changes to their positions in the business. Foster Dykema Cabot & Partners LLC bought a new position in Organon & Co. in the 3rd quarter worth approximately $29,000. Farther Finance Advisors LLC raised its position in shares of Organon & Co. by 87.8% during the fourth quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after buying an additional 2,033 shares during the last quarter. Rothschild Investment LLC lifted its holdings in shares of Organon & Co. by 73.1% in the third quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after buying an additional 1,646 shares in the last quarter. Eurizon Capital SGR S.p.A. purchased a new position in shares of Organon & Co. in the fourth quarter worth $44,000. Finally, Kestra Advisory Services LLC bought a new position in shares of Organon & Co. during the fourth quarter worth $47,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.